Trial Profile
A retrospective study of lenalidomide dose modification, duration of therapy and long-term outcomes in patients with myelodysplastic syndrome.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 22 Jan 2018
Price :
$35
*
At a glance
- Drugs Lenalidomide (Primary)
- Indications Myelodysplastic syndromes
- Focus Therapeutic Use
- 22 Jan 2018 New trial record
- 01 Dec 2017 Results assessing relationship between lenalidomide dose modification, duration of therapy, and long-term outcomes in patients with myelodysplastic syndromes, were published in the Leukemia Research.